This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2012 Feb 10;30(5):e64-8.

doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27.

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

Vivek Subbiah¹, John Slopis, David S Hong, Leena M Ketonen, Jackson Hamilton, Ian E McCutcheon, Razelle Kurzrock

Affiliations

PMID: 22203760
PMCID: PMC3295556
DOI: 10.1200/JCO.2011.38.2614

Clinical Trial

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

Vivek Subbiah et al. J Clin Oncol. 2012.

. 2012 Feb 10;30(5):e64-8.

doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27.

Authors

Vivek Subbiah¹, John Slopis, David S Hong, Leena M Ketonen, Jackson Hamilton, Ian E McCutcheon, Razelle Kurzrock

Affiliation

¹ The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. vsubbiah@mdanderson.org

PMID: 22203760
PMCID: PMC3295556
DOI: 10.1200/JCO.2011.38.2614

No abstract available

PubMed Disclaimer

Figures

Fig 1. — Fig 1.

Fig 2. — Fig 2.

Fig 3. — Fig 3.

See this image and copyright information in PMC

Similar articles

Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud A. Ravaud A. Oncologist. 2011;16 Suppl 2(Suppl 2):32-44. doi: 10.1634/theoncologist.2011-S2-32. Oncologist. 2011. PMID: 21346038 Free PMC article. Review.
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S, Choueiri TK. Chowdhury S, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):373-9. doi: 10.1586/14737140.9.3.373. Expert Rev Anticancer Ther. 2009. PMID: 19275514 Review.
[Adverse effects of new oncologic therapies].
Weisshaupt Ch, Budak K, Pestalozzi B. Weisshaupt Ch, et al. Praxis (Bern 1994). 2011 Jul 27;100(15):885-91; quiz 890. doi: 10.1024/1661-8157/a000609. Praxis (Bern 1994). 2011. PMID: 21792802 German. No abstract available.
[Targeted therapies and their indications in solid neoplasias].
Dreyer C, Raymond E, Faivre S. Dreyer C, et al. Rev Med Interne. 2009 May;30(5):416-24. doi: 10.1016/j.revmed.2008.12.022. Epub 2009 Mar 18. Rev Med Interne. 2009. PMID: 19299048 Review. French.
Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S. Gettinger S. Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. doi: 10.1055/s-2008-1076749. Semin Respir Crit Care Med. 2008. PMID: 18506667 Review.

See all similar articles

Cited by

Management Strategies of Neurofibromatosis Type 2 in Pediatric Patients : Challenges and Emerging Therapies.
Lee JS. Lee JS. J Korean Neurosurg Soc. 2025 May;68(3):278-285. doi: 10.3340/jkns.2024.0237. Epub 2025 Feb 24. J Korean Neurosurg Soc. 2025. PMID: 39988763 Free PMC article.
Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Moulder S, et al. Ann Oncol. 2015 Jul;26(7):1346-52. doi: 10.1093/annonc/mdv163. Epub 2015 Apr 15. Ann Oncol. 2015. PMID: 25878190 Free PMC article.
Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1.
Deshpande A, Munoz J, Dabak V, Hanbali A, Kurzrock R. Deshpande A, et al. J Immunother Precis Oncol. 2024 May 2;7(2):122-125. doi: 10.36401/JIPO-23-32. eCollection 2024 May. J Immunother Precis Oncol. 2024. PMID: 38721407 Free PMC article.
Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review.
Tops AL, Schopman JE, Koot RW, Gelderblom H, Putri NA, Rahmi LNA, Jansen JC, Hensen EF. Tops AL, et al. Cancers (Basel). 2025 Feb 4;17(3):519. doi: 10.3390/cancers17030519. Cancers (Basel). 2025. PMID: 39941885 Free PMC article. Review.
Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses.
Nikanjam M, Wells K, Kato S, Adashek JJ, Block S, Kurzrock R. Nikanjam M, et al. Med. 2024 Jul 12;5(7):689-717. doi: 10.1016/j.medj.2024.04.008. Epub 2024 May 14. Med. 2024. PMID: 38749442 Free PMC article. Review.

See all "Cited by" articles

References

1. Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet. 2009;373:1974–1986. - PMC - PubMed
1. Evans DG. Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet J Rare Dis. 2009;4:16. - PMC - PubMed
1. Lu-Emerson C, Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009;6:E81–E86. - PubMed
1. Baser ME, R Evans DG, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol. 2003;16:27–33. - PubMed
1. Plotkin SR, Stemmer-Rachamimov AO, Barker FG, 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–367. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal